| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Xiujuan Fu | Q88411421 |
| Wei Chen | Q88411424 | ||
| P2093 | author name string | Lili Wang | |
| Yadan Chen | |||
| Guowei Zhao | |||
| Haiming Ma | |||
| Dasheng Zhu | |||
| P2860 | cites work | Cloning of adiponectin receptors that mediate antidiabetic metabolic effects | Q24304889 |
| MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone | Q24671640 | ||
| Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions | Q57249776 | ||
| A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones | Q73905024 | ||
| Acute mitochondrial actions of glitazones on the liver: a crucial parameter for their antidiabetic properties | Q83009944 | ||
| A novel MitoNEET ligand, TT01001, improves diabetes and ameliorates mitochondrial function in db/db mice | Q86273410 | ||
| Improvement of insulin sensitivity by a novel drug candidate, BGP-15, in different animal studies | Q87029783 | ||
| [Adiponectin receptor-targeted therapy for lifestyle-related diseases] | Q87386873 | ||
| A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499. | Q42833061 | ||
| L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation | Q42834558 | ||
| Decreased expression of heat shock protein 72 in skeletal muscle of patients with type 2 diabetes correlates with insulin resistance | Q43935456 | ||
| Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice | Q44504595 | ||
| Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism | Q44564039 | ||
| Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases | Q44635317 | ||
| Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects | Q45161422 | ||
| Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: a proof of concept randomized double-blind clinical trial | Q46123055 | ||
| Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice | Q46442810 | ||
| TGF-β1/Smad3 Pathway Targets PP2A-AMPK-FoxO1 Signaling to Regulate Hepatic Gluconeogenesis | Q48364918 | ||
| HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models. | Q51317723 | ||
| Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. | Q51554900 | ||
| Metformin action: concentrations matter. | Q52970022 | ||
| Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue. | Q53514538 | ||
| Metformin Activates AMPK through the Lysosomal Pathway. | Q55014616 | ||
| Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones | Q26745533 | ||
| AMPK activators: mechanisms of action and physiological activities | Q26749158 | ||
| Metrnl: a secreted protein with new emerging functions | Q26750482 | ||
| Adiponectin signaling and function in insulin target tissues | Q26753354 | ||
| Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity | Q26777180 | ||
| Insulin receptor signaling in normal and insulin-resistant states | Q26823171 | ||
| Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review | Q26866784 | ||
| The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis | Q27002036 | ||
| Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice | Q28077057 | ||
| Mitochondrial pyruvate transport: a historical perspective and future research directions | Q28085025 | ||
| Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe | Q28211498 | ||
| Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer | Q28244332 | ||
| BGP-15 Protects against Oxidative Stress- or Lipopolysaccharide-Induced Mitochondrial Destabilization and Reduces Mitochondrial Production of Reactive Oxygen Species | Q28468438 | ||
| Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319 | Q28487909 | ||
| Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins | Q28488095 | ||
| The adipocyte-secreted protein Acrp30 enhances hepatic insulin action | Q28505765 | ||
| Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster | Q28538170 | ||
| CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo | Q28540538 | ||
| A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes | Q28590335 | ||
| Membrane-lipid therapy in operation: the HSP co-inducer BGP-15 activates stress signal transduction pathways by remodeling plasma membrane rafts | Q28741590 | ||
| Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization | Q29028203 | ||
| Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity | Q33641373 | ||
| Activating HSP72 in rodent skeletal muscle increases mitochondrial number and oxidative capacity and decreases insulin resistance | Q33646728 | ||
| AMPK activation: a therapeutic target for type 2 diabetes? | Q33824564 | ||
| The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy | Q33932723 | ||
| Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice | Q33976093 | ||
| Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists | Q34011043 | ||
| An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. | Q34126021 | ||
| Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates | Q34201490 | ||
| A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity | Q34249161 | ||
| Insulin resistance: definition and consequences | Q34312005 | ||
| Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. | Q34330155 | ||
| A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity | Q34381237 | ||
| A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role | Q34389286 | ||
| Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone | Q34511474 | ||
| The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. | Q34522920 | ||
| PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome | Q34566145 | ||
| Differentiating members of the thiazolidinedione class: a focus on safety | Q34580994 | ||
| LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys | Q34792753 | ||
| Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice | Q35108463 | ||
| Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation | Q35230678 | ||
| Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy | Q35368220 | ||
| Adipokines as drug targets in diabetes and underlying disturbances. | Q35415815 | ||
| Heat shock proteins as emerging therapeutic targets | Q35545091 | ||
| Fibroblast growth factor 21: a novel metabolic regulator | Q35770027 | ||
| Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models | Q35822331 | ||
| AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings | Q35916840 | ||
| A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis | Q35981284 | ||
| PPARgamma in human and mouse physiology | Q36063081 | ||
| Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals | Q36246086 | ||
| Novel ligands that target the mitochondrial membrane protein mitoNEET | Q36337739 | ||
| Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? | Q36411656 | ||
| HSP72 protects against obesity-induced insulin resistance | Q36446531 | ||
| Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells | Q36492756 | ||
| Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling. | Q36578665 | ||
| Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer | Q36705829 | ||
| Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. | Q36747796 | ||
| AMPK, insulin resistance, and the metabolic syndrome | Q36966839 | ||
| Systemic fate of the adipocyte-derived factor adiponectin | Q37317454 | ||
| Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. | Q37426678 | ||
| Suppression of the mTORC1/STAT3/Notch1 pathway by activated AMPK prevents hepatic insulin resistance induced by excess amino acids | Q37575390 | ||
| Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. | Q37602774 | ||
| Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation | Q37631296 | ||
| 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development | Q37656439 | ||
| Review article: Thiazolidinediones and heart failure | Q37724501 | ||
| Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. | Q37835820 | ||
| Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy | Q37864207 | ||
| Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist | Q37988915 | ||
| 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? | Q38015005 | ||
| Metformin: the hidden chronicles of a magic drug | Q38062136 | ||
| 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome | Q38067260 | ||
| A review on thiazolidinediones and bladder cancer in human studies | Q38193601 | ||
| AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease | Q38211516 | ||
| PPAR gamma gene--a review | Q38275755 | ||
| AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity | Q38292405 | ||
| Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists | Q38318111 | ||
| Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis | Q38361016 | ||
| Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells | Q38475375 | ||
| Unraveling the actions of AMP-activated protein kinase in metabolic diseases: Systemic to molecular insights | Q38810023 | ||
| MiR-577 inhibits pancreatic β-cell function and survival by targeting fibroblast growth factor 21 (FGF-21) in pediatric diabetes | Q38814512 | ||
| Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling | Q38837452 | ||
| Inhibition of 11β-HSD1 by LG13 improves glucose metabolism in type 2 diabetic mice | Q38848426 | ||
| Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells | Q38972153 | ||
| Fibroblast growth factor 21 and its novel association with oxidative stress | Q39063540 | ||
| C333H ameliorated insulin resistance through selectively modulating peroxisome proliferator-activated receptor γ in brown adipose tissue of db/db mice | Q39170002 | ||
| His-87 ligand in mitoNEET is crucial for the transfer of iron sulfur clusters from mitochondria to cytosolic aconitase | Q40096858 | ||
| Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. | Q40895648 | ||
| Fgf signaling in adipocytes as a target for metabolic diseases | Q41861232 | ||
| Metformin directly acts on mitochondria to alter cellular bioenergetics. | Q41897802 | ||
| Chloroquine augments the binding of insulin to its receptor. | Q41932285 | ||
| The rôle of mitochondrial pyruvate transport in the stimulation by glucagon and phenylephrine of gluconeogenesis from L-lactate in isolated rat hepatocytes | Q42095303 | ||
| Role of glucose and insulin in thiazolidinedione-induced alterations in hepatic gluconeogenesis | Q42496667 | ||
| Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action | Q42553431 | ||
| Adipocyte Metrnl Antagonizes Insulin Resistance Through PPARγ Signaling. | Q42823688 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 8360919 | |
| P577 | publication date | 2017-06-04 | |
| P1433 | published in | PPAR Research | Q15756406 |
| P1476 | title | Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets | |
| P478 | volume | 2017 |
| Q89638973 | Ficus deltoidea extract down-regulates protein tyrosine phosphatase 1B expression in a rat model of type 2 diabetes mellitus: a new insight into its antidiabetic mechanism |
| Q90448406 | Identification and structural insight of an effective PPARγ modulator with improved therapeutic index for anti-diabetic drug discovery |
| Q99414120 | Molecules Isolated from Mexican Hypoglycemic Plants: A Review |
| Q92864499 | PAHSAs enhance hepatic and systemic insulin sensitivity through direct and indirect mechanisms |
| Q50317594 | Portulaca Extract Attenuates Development of Dextran Sulfate Sodium Induced Colitis in Mice through Activation of PPARγ. |
| Q58610751 | Trans-repression of NFκB pathway mediated by PPARγ improves vascular endothelium insulin resistance |
Search more.